Cargando…

P010: Inferior Outcomes for Young Adults Treated on Advanced Stage Clinical Trials: Report from the HoLISTIC Consortium

Detalles Bibliográficos
Autores principales:	Parsons, Susan K., Rodday, Angie Mae, Friedberg, Jonathan W., Gallamini, Andrea, Hawkes, Eliza, Hodgson, David, Johnson, Peter, Link, Brian, Maurer, Matthew, Nelson, Jason, Savage, Kerry J., Upshaw, Jenica, Zinzani, Pier Luigi, Evens, Andrew M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Advanced Stages
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621523/ http://dx.doi.org/10.1097/01.HS9.0000890608.32200.eb

Ejemplares similares

P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1
por: Hutchings, Martin, et al.
Publicado: (2022)

P004: Advanced stage classical Hodgkin lymphoma (cHL) patients with a positive interim-PET (PET-2) Deauville score (DS) 5 after 2 ABVD cycles: A pooled analysis of individual patient data of three multicenter trials
por: Viviani, Simonetta, et al.
Publicado: (2022)

T021: Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial.
por: Gallamini, Andrea, et al.
Publicado: (2022)

T083: The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma
por: Upshaw, Jenica, et al.
Publicado: (2022)

Association of Treatment Intensity With Survival in Older Patients With Hodgkin Lymphoma
por: Rodday, Angie Mae, et al.
Publicado: (2021)

42P Radiation induced pneumonitis in the era of the COVID-19 pandemic: Artificial intelligence for differential diagnosis
por: Ramella, S., et al.
Publicado: (2021)

44P Inter-reader variability of lung parenchymal observations on chest CT among COVID-19 RT-PCR negative lung cancer patients treated with chemo-radiation: Potential pitfalls of pulmonary findings in different readers with various experience levels
por: Jajodia, A., et al.
Publicado: (2021)

43P Incidentally discovered suspicious lung lesions in hospitalized patients during the COVID-19 pandemic in Georgia
por: Abuladze, M., et al.
Publicado: (2021)

Impact of the Covid-19 pandemic on a District General Hospital EBUS service
por: Wright, Matthew, et al.
Publicado: (2021)

P007: Comparative efficacy of the R-BEACOPP-14 and R-CHOP regimens in the treatment of patients with advanced stages of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with THRLBCL-like histopathological growth patterns in the tumor biopsy
por: Dorokhina, Elena, et al.
Publicado: (2022)

T001: FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial
por: Diepstra, Arjan, et al.
Publicado: (2022)

P017: The role of baseline bulk and dissemination measures as predictors of progression in advanced Hodgkin lymphoma
por: Taszner, Michal, et al.
Publicado: (2022)

P014: Prognostic significance of nutritional indexes (CONUT and PNI) in classical Hodgkin lymphoma patients
por: Sousa, Rita Costa E., et al.
Publicado: (2022)

T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group
por: Borchmann, Peter, et al.
Publicado: (2022)

P013: Outcomes of first-line treatment (FL) of classical Hodgkin lymphoma (cHL) in Argentina: a real life multicenter retrospective study
por: Laura, Korin, et al.
Publicado: (2022)

P011: IPS-7 or IPS-3 to identify very-high risk patients in advanced Classical Hodgkin’s Lymphoma: Which score to choose
por: Almeida, Cátia, et al.
Publicado: (2022)

P016: Reduced steroid exposure is safe and does not reduce disease control among Hodgkin Lymphoma patients treated with escalated BEACOPP (eBEACOPP)
por: Dragičević, Ida Hude, et al.
Publicado: (2022)

P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi
por: Rusconi, Chiara, et al.
Publicado: (2022)

P012: Nodular Lymphocyte-predominant Hodgkin Lymphoma a rare disease with good prognosis: a retrospective multicenter experience
por: Pierdomenico, Francesca, et al.
Publicado: (2022)

T022: Sharing decisions regarding radiotherapy for Hodgkin lymphoma: a qualitative study of the experiences of patients and clinicians in the UK
por: Shakir, Rebecca, et al.
Publicado: (2022)

P023: PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma
por: Mocikova, Heidi, et al.
Publicado: (2022)

P005: Age, histotype and stage IV are associated with a shorter survival in patients with Hodgkin lymphoma, even the PET-adapted era. A single center retrospective study.
por: Visentin, Andrea, et al.
Publicado: (2022)

P015: Real World Escalated BEACOPDac Delivers Similar Outcomes to Escalated BEACOPP While Potentially Reducing Haematopoietic and Reproductive Toxicity
por: Santarsieri, Anna, et al.
Publicado: (2022)

P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial
por: Van Heek, Lutz, et al.
Publicado: (2022)

P003: A retrospective study to evaluate the reliability of staging and risk stratification of adolescent and adult patients with Hodgkin’s lymphoma registered in the lymphoma clinic at Tata Memorial Centre.
por: Jain, Hasmukh, et al.
Publicado: (2022)

P008: Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma
por: Voltin, Conrad-Amadeus, et al.
Publicado: (2022)

P019: Unfavorable prognostic value of the predominance of THRLBCL-like histopathological growth patterns in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)
por: Dorokhina, Elena, et al.
Publicado: (2022)

P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma
por: Radford, John, et al.
Publicado: (2022)

T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies
por: Eichenauer, Dennis A., et al.
Publicado: (2022)

P018: Treatment outcomes in classical Hodgkin lymphoma (HL): 5-year update report from the Brazilian Prospective Registry
por: Biasoli, Irene, et al.
Publicado: (2022)

Increased proportion of patients diagnosed with lung cancer as a result of an acute hospital admission during the COVID-19 pandemic, and associated inequalities
por: Taylor, Rebecca
Publicado: (2023)

Impact of COVID 19 on EBUS services
por: Dugdale, Isobel, et al.
Publicado: (2023)

Effects of Prenatal Exposure to Alcohol Across the Life Span
por: Connor, Paul D., et al.
Publicado: (1996)

Effect of Parental Drinking on Adolescents
por: Windle, Michael
Publicado: (1996)

Alcohol in the Early Years of Marriage
por: Leonard, Kenneth E., et al.
Publicado: (1996)

Late-Life Drinking Behavior: The Influence of Personal Characteristics, Life Context, and Treatment
por: Brennan, Penny L., et al.
Publicado: (1996)

Drinking During Adolescence
por: Chassin, Laurie, et al.
Publicado: (1996)

Drinking Among Young Adults: Prevalence, Patterns, and Consequences
por: Quigley, Lori A., et al.
Publicado: (1996)

FIGO staging of endometrial cancer: 2023
por: Berek, Jonathan S., et al.
Publicado: (2023)

Measuring global health-related quality of life in children undergoing hematopoietic stem cell transplant: a longitudinal study
por: Rodday, Angie Mae, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_387gc6snm94jinh645c4l6p8td